investigating the effect of pomegranate extract in asthma

Evaluating the effect of pomegranate extract on some serum immunologic factors(IL-35? hs-CRP), oxidative stress status (PAB) and spirometry test in patients with persistent allergic asthma with mild and moderate severity

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200205046384N1

Enrollment

Registered

2020-05-09

Start date

2020-04-20

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma. ???

Interventions

Intervention 1: Intervention group: group receiving pomegranate extract 500 mg / day in capsule form (two 250 mg capsules daily). Drug production center: The institute of medicinal plants research o

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Ages 18 to 65 years Patients with mild to moderate persistent allergic asthma, Forced Expiratory Volume in First Second(FEV1) greater than 60% Body mass index(BMI):18.5-30 Both sexes

Exclusion criteria

Exclusion criteria: smoking Diabetes Pregnancy and lactation Autoimmune diseases Malignancies Digestive, liver or kidney problems Pneumonia Other pulmonary diseases Antioxidant usage blood pressure-lowering drugs (Statin and ACE Inhibitors)

Design outcomes

Primary

Measure	Time frame
Prooxidant-antioxidant balance. Timepoint: at the beginning of the study and 8 weeks after the intervention. Method of measurement: Based on blood test using calorimetry.;Forced Vital Capacity(FVC)/Forced Expiratory Volume in First Second(FEV1)? FEV1? FVC. Timepoint: at the beginning of the study and 8 weeks after the intervention. Method of measurement: Based on the result of the spirometer- Variable scale: percent.	—

Measure

Time frame

Prooxidant-antioxidant balance. Timepoint: at the beginning of the study and 8 weeks after the intervention. Method of measurement: Based on blood test using calorimetry.;Forced Vital Capacity(FVC)/Forced Expiratory Volume in First Second(FEV1)? FEV1? FVC. Timepoint: at the beginning of the study and 8 weeks after the intervention. Method of measurement: Based on the result of the spirometer- Variable scale: percent.

—

Secondary

Measure	Time frame
High sensitivity C-reactive protein (hsCRP). Timepoint: At the beginning of the study and 8 weeks after intervention. Method of measurement: Laboratory measurement (quantitative luminescence) - mg / dl.;Blood pressure. Timepoint: At the beginning of the study and 8 weeks after the intervention. Method of measurement: Based on the results of the Easy Life aneroid Sphygmomanometer-mmHg.;Clinical variables and general patient status. Timepoint: At the beginning of the study and 8 weeks after the intervention. Method of measurement: Based on a questionnaire filled by a specialist physician.;IL-35. Timepoint: At the beginning of the study and 8 weeks after the intervention. Method of measurement: Based on laboratory measurements-pg/ml.;Complete blood cell count and differential count. Timepoint: At the beginning of the study and 8 weeks after the intervention. Method of measurement: Based on laboratory measurement.	—

Measure

Time frame

High sensitivity C-reactive protein (hsCRP). Timepoint: At the beginning of the study and 8 weeks after intervention. Method of measurement: Laboratory measurement (quantitative luminescence) - mg / dl.;Blood pressure. Timepoint: At the beginning of the study and 8 weeks after the intervention. Method of measurement: Based on the results of the Easy Life aneroid Sphygmomanometer-mmHg.;Clinical variables and general patient status. Timepoint: At the beginning of the study and 8 weeks after the intervention. Method of measurement: Based on a questionnaire filled by a specialist physician.;IL-35. Timepoint: At the beginning of the study and 8 weeks after the intervention. Method of measurement: Based on laboratory measurements-pg/ml.;Complete blood cell count and differential count. Timepoint: At the beginning of the study and 8 weeks after the intervention. Method of measurement: Based on laboratory measurement.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZainab Shateri

Ahvaz University of Medical Sciences

shateri.z@ajums.ac.ir0098613311

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 11, 2026